A leading Indian chemical manufacturing powerhouse, renowned for its innovative pharmaceutical intermediates and speciality chemicals, has made waves in the international market. The company’s recent strategic alliance with a prominent Japanese firm signals a significant expansion in its global footprint, promising to leverage advanced chemistry techniques in a multi-year collaboration.
Share Price Movement
The share price of Shree Ganesh Remedies Limited hit a 20 percent upper circuit of Rs. 889.65 per share on Friday, an increase from its previous close of Rs. 741.40 per share. The market capitalisation now stands at approximately Rs. 1,052 crore as of January 31, 2025.
What Happened
Has signed a long-term MOU agreement with a top Japanese company to manufacture three innovative chemical products. The deal, starting January 30, 2025, lasts three years (extendable by two) and uses advanced chemistry techniques.
Financial Highlights
In Q2FY25, revenue stood at Rs. 32.33 crore, down 3.3% YoY from Rs. 33.42 crore but up 30.5% QoQ from Rs. 24.78 crore. Profit for Q2FY25 was Rs. 6.42 crore, declining 2% YoY from Rs. 6.55 crore but rising 38.1% QoQ from Rs. 4.65 crore.
Also read….
Competitors
Shree Ganesh Remedies Ltd.’s competitors include Sun Pharma, Cipla, Mankind Pharma, Dr. Reddy’s Labs, Zydus Lifesciences, Lupin, and Aurobindo Pharma.
Shree Ganesh Remedies has a P/E of 37.08, which is higher than the industry P/E of 30.68.
Market Outlook
India’s pharmaceutical intermediates and speciality chemicals industry is set for strong growth, driven by rising demand for generics and chronic disease treatments. Government support, cost advantages, and innovation in biologics and drug delivery fuel expansion. Despite challenges like supply chain disruptions and regulations, India remains a key global supplier.
The country’s pharma exports, exceeding $25 billion, highlight its resilience. With increasing global investment in biopharmaceuticals, India’s role in drug production and innovation is expected to grow further.
Written By Fazal Ul Vahab C H
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
